Connexin 31.1 inhibitors are a specific class of chemical compounds designed to target and inhibit Connexin 31.1, a protein that forms part of the connexin family, which is integral to the formation of gap junctions in cell membranes. Connexin 31.1 is known to play a role in intercellular communication by facilitating the passage of ions and small molecules between adjacent cells, a process essential for maintaining various physiological functions. The inhibition of Connexin 31.1 by these compounds can have significant effects on cell signaling and tissue homeostasis. The molecular design of Connexin 31.1 inhibitors involves structures that can selectively bind to and disrupt the normal function of Connexin 31.1. This is achieved through the incorporation of functional groups and structural motifs that interfere with the formation or functioning of gap junctions. These inhibitors often feature specific arrangements of rings, chains, and functional groups like hydrogen bond donors or acceptors, which are strategically placed to optimize the interaction with Connexin 31.1 and enhance the specificity and efficacy of the inhibition.
The development of Connexin 31.1 inhibitors is a complex and interdisciplinary process, involving insights from the fields of chemistry, structural biology, and computational modeling. Structural studies of Connexin 31.1, employing techniques such as X-ray crystallography or NMR spectroscopy, provide essential information about the protein's configuration and its mechanism of forming gap junctions. This structural knowledge is critical for the rational design of molecules that can effectively target and inhibit Connexin 31.1. In the realm of synthetic chemistry, various compounds are synthesized and tested for their ability to interact with Connexin 31.1. These compounds undergo rigorous modification and optimization to enhance their binding affinity, specificity, and overall stability. Additionally, the physicochemical properties of Connexin 31.1 inhibitors, such as solubility, stability, and bioavailability, are key considerations. These properties are finely tuned to ensure that the inhibitors are not only effective in their interaction with Connexin 31.1 but also suitable for use in various biological systems. The development of Connexin 31.1 inhibitors underscores the complexity of targeting specific proteins that play crucial roles in cellular communication, reflecting the sophisticated interplay between chemical structure and biological function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $39.00 $59.00 $104.00 $206.00 | 8 | |
Binds to heat shock protein 90 (Hsp90) and may disrupt its chaperone function, potentially affecting the stability of client proteins including connexin 31.1. | ||||||
2-Methoxyestradiol | 362-07-2 | sc-201371 sc-201371A | 10 mg 50 mg | $71.00 $288.00 | 6 | |
Downregulates hypoxia-inducible factors which could indirectly decrease connexin 31.1 expression under specific conditions. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Proteasome inhibitor that can lead to altered protein turnover, potentially reducing connexin 31.1 levels due to increased degradation. | ||||||
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $110.00 $250.00 $936.00 $50.00 | 33 | |
Has been shown to modulate protein kinase pathways and gene transcription, potentially affecting connexin 31.1 expression. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Inhibits N-linked glycosylation, which could theoretically impact the stability and expression of glycoproteins like connexin 31.1. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A proteasome inhibitor that can prevent the degradation of ubiquitinated proteins, potentially altering the level of connexin 31.1. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Isoflavone that acts as a tyrosine kinase inhibitor, which could influence signal transduction pathways affecting gene expression. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Modulates multiple signaling pathways which may result in downregulation of certain genes, including potentially connexin 31.1. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A selective inhibitor of MEK, which may alter the MAPK pathway and impact the expression of various genes, possibly including connexin 31.1. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor, which could affect signaling pathways involved in the regulation of gene expression, including that of connexin 31.1. | ||||||